What does the FDC Limited (FDC) stock page cover?

FDC Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for FDC?

FDC Limited is currently shown with a delayed price near ₹377, P/E 19.59.

Does the FDC page provide investment advice?

No. The FDC page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Stocks›Healthcare

Watch Alert

FDC Limited

FDC · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹377.00

−₹0.15 (−0.04%)(1D)

₹312.9552 Week Range₹473.60

Anvest Score

64/100

Valuation

67/100

Quality

55/100

Growth

57/100

Health

100/100

Momentum

46/100

Valuation
67
Quality
55
Growth
57
Health
100
Momentum
46

Loading company profile…

More Page Context

Research at a glance

FDC Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹377

Market cap

₹6,140 Cr

P/E ratio

19.59

P/B ratio

2.47

Dividend yield

Not available

ROE

Not available

RSI 14

67.26

1Y return

Not available

FDC Limited FAQs

3 topics

Expand

Stocks›Healthcare

Watch Alert

FDC Limited

FDC · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹377.00

−₹0.15 (−0.04%)(1D)

₹312.9552 Week Range₹473.60

Anvest Score

64/100

Valuation

67/100

Quality

55/100

Growth

57/100

Health

100/100

Momentum

46/100

Valuation
67
Quality
55
Growth
57
Health
100
Momentum
46

AI Company ProfileSign in to generate AI briefing

AI Snapshot

FDC Limited is an Indian pharmaceutical company manufacturing and trading formulations and Active Pharmaceutical Ingredients (APIs). It sells branded generic drugs and APIs domestically and exports to over 50 countries, with the US as a key market.

Drug Manufacturers - Specialty & GenericFounded:1936CEO/MD:Nandan ChandavarkarHQ:Mumbai, Maharashtra

Business profile as of 2026-08-25

Business at a Glance

Key brands include Electral and Enerzal.
The company focuses on both branded generics and over-the-counter (OTC) products across various therapeutic areas, leveraging its research and development capabilities and extensive distribution network.

Revenue growth: +3.0%FY26 growth+6.8%3Y CAGR
EPS growth: +5.5%FY26 growth+14.0%3Y CAGR
CFO / PAT: 0.71×FY26

What Looks Strong

GrowthNet profit grew at +13.2% CAGR over three years.

What to Watch

No material watchpoint identified from currently verified evidence.

Reports a single operating segment in its results filings.
FDC Limited generates revenue by developing, manufacturing, and selling pharmaceutical products, including finished dosage forms and active pharmaceutical ingredients (APIs).
The company's product portfolio covers therapeutic segments like anti-infectives, gastrointestinal treatments, and ophthalmics.

FY26 (consolidated): revenue ₹2,171 cr, up 3% from ₹2,108 cr in FY25; net profit ₹281 cr, up 5% from ₹267 cr in FY25.
FY26 (consolidated): operating cash flow ₹200 cr (0.7× net profit); debt/equity 0.00×.
Latest quarter to Sep 2026 (consolidated): revenue ₹572 cr (up 21% year on year); net profit ₹49.1 cr.

The company's financial results are audited by BSR&Co.LLP, who confirm the accuracy and completeness of accounting records for a true…

Loading company profile…

More Page Context

Research at a glance

FDC Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹377

Market cap

₹6,140 Cr

P/E ratio

19.59

P/B ratio

2.47

Dividend yield

Not available

ROE

Not available

RSI 14

67.26

1Y return

Not available

FDC Limited FAQs

3 topics

Expand

FDC Limited

Research at a glance

FDC Limited FAQs

FDC Limited

Business at a Glance

What Looks Strong

What to Watch

Research at a glance

FDC Limited FAQs

Related paths

Related insights

MOREPENLAB

INNOVACAP

SPARC

Backtesting FII, DII, and Promoter Shareholding Changes in Indian Small & Mid-Caps

Business at a Glance

What Looks Strong

What to Watch